Basic Provisions of Program. (a) The objective of the Research Program will be to generate Project Data Sets by performing Research Projects utilizing GENENTECH Proprietary Material. CURAGEN and GENENTECH shall each use commercially reasonable efforts to 10 perform such tasks as are set forth in the Research Plan, including the provision of such facilities, samples and materials (including GENENTECH Proprietary Material), equipment and consultants as each deems necessary to the achievement of such Research Plan. In carrying out the Research Program, CURAGEN shall devote an average of at least [XXXXX] FTEs per year to the Research Program over its five year duration (the "Staffing Level") unless GENENTECH and CURAGEN have agreed on an increase in the Staffing Level as provided in (b) below.
Basic Provisions of Program. (a) The objective of the Research Program will be for CURAGEN to generate and deliver to BIOGEN Project Data Sets by performing Research Projects utilizing BIOGEN Proprietary Material. CURAGEN shall use commercially reasonable efforts to perform such tasks as are set forth in the Research Plan, including use of its functional genomics technologies (including GeneScape(R), QEA/GeneCalling, MIM/PathCalling and all additional services provided by CURAGEN) and the provision of such facilities and materials (other than BIOGEN Proprietary Material), equipment and consultants as it deems necessary to the achievement of such Research Plan and shall deliver each Project Data Set to BIOGEN using the GeneScape(R) database and software. In carrying out the Research Program, CURAGEN shall devote an average of at least [XXXXXXXX] FTEs per year to the Research Program over its five year duration (the "Staffing Level") unless BIOGEN and CURAGEN have agreed on a change in the Staffing Level as provided in (b) below. (b) BIOGEN may request an increase in the Staffing Level of up to [XXX XXX] additional FTEs per year to be devoted to the Research Program, subject to the agreement of CURAGEN. CURAGEN will use commercially reasonable efforts to increase the staffing level if mutually agreed as promptly as practical. Once the Staffing Level is increased, it may not be decreased during the following [XXXXXXXXX] period without the consent of CURAGEN, which consent shall not be unreasonably withheld.
Basic Provisions of Program. (a) The primary objective of the R&D Program shall be the identification and development of [*****] Enzymes providing enhanced or new properties useful in the [*****]. The Research [*****] indicates the progress expected to occur under this Agreement; namely, from [*****] discovery to [*****] Enzyme to identification of a Licensed [*****]. Once a Licensed [*****] is identified then the License Agreement pertains for the remainder of the [*****].
Basic Provisions of Program. (a) The objective of the R&D Program shall be the discovery and characterization of genes associated with plant growth and development, [XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX]. CURAGEN and PIONEER shall each use commercially reasonable efforts to perform such tasks as are set forth to be performed by it in the Work Plans, including the provision of such facilities, materials (including PIONEER Proprietary Materials), equipment and consultants as each deems necessary to the achievement of such Work Plans. In carrying out the R&D Program, CURAGEN shall devote an average of at least [XXXXXXXX] FTEs per year, including [XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX] to the R&D Program over its five year duration (the "Staffing Level") unless PIONEER has requested an increase in the Staffing Level as provided in (b) below. At least one FTE, who shall be an individual reasonably acceptable to PIONEER, shall be devoted to the R&D Program on a full-time basis.
Basic Provisions of Program. The objective of the Research Phase of the R & D Program shall be the discovery and characterization of Accepted Targets in areas covered by the four Activity Profiles contained in Exhibit 1 and any other Activity Profiles designated by the JSC from time to time. The objective of the development phase of the R & D Program shall be the development of Compounds receiving Pre-Project Status designation and the testing and regulatory approval of Antibacterial Products in areas covered by such Activity Profiles. In carrying out the R & D Program, CHEMGENICS shall devote an average of at least [ ] full-time equivalent employees per year to the Research Phase of the R & D Program over its five year duration, and shall ensure that a reasonable number of such employees are devoted solely to the R &
Basic Provisions of Program. (a) The objectives of the R&D Program, as further described in Exhibit A attached hereto, shall be to successfully complete the following phases (each, a “Phase”): * apply for and obtain regulatory approvals for commercial crop cultivation, and generate sufficient DHA-rich seed to support pre-commercialization studies for a plant-based DHA product and achieve commercial approval.
Basic Provisions of Program. (a) The primary objective of the R&D Program shall be the identification and development of Enzymes as Licensed Enzymes providing enhanced or new properties useful in the Project Field.
Basic Provisions of Program. (a) The primary objective of the R&D Program shall be the identification, development and commercialization of Licensed Enzymes providing enhanced or new properties useful in the Approved Fields. The Research Project Flow Chart in Appendix G indicates the progress expected to occur under this IE R&D Agreement; namely, [***]. Once a Licensed Enzyme is identified then the Development Agreement (as defined in the LLC License) and other terms of the LLC Agreement pertain for the remainder of the Chart.
Basic Provisions of Program. (a) The objectives of the R&D Program, as further described in Exhibit A attached hereto, shall be to successfully complete the following phases (each, a “Phase”): I) establish POC in * for the production of DHA using MARTEK’s PKS technology, II) establish POC in commercial crop species *, III) develop a commercial * cultivar, and IV) apply for and obtain regulatory approvals for commercial crop cultivation, and generate sufficient DHA-rich seed to support pre-commercialization studies for a plant-based DHA product and achieve commercial approval.
Basic Provisions of Program. (a) The objective of the Research Program will be to generate Project Data Sets by performing Research Projects utilizing GENENTECH Proprietary Material. CURAGEN and GENENTECH shall each use commercially reasonable efforts to perform such tasks as are set forth in the Research Plan, including the provision of such facilities, samples and materials (including GENENTECH Proprietary Material), equipment and consultants as each deems necessary to the achievement of such Research Plan. GENENTECH may, at its option, propose that the Parties perform up to one (1) new Research Project each Research Quarter, which proposal shall be approved and conducted in accordance with Section 2.1.3 of this Agreement. In carrying out the Research Program, CURAGEN shall devote a number of FTEs to the Research Program as is sufficient to enable it to complete all Initial Research Projects and also to initiate one (1) new Research Project per Research Quarter, commencing on July 1, 2000, up to a maximum of ten (10) new Research Projects in the aggregate, and to complete such new Research Projects
